Skip to main content

Home

Login or Register

Donate

  • Follow @theprospect
  •  
  • Newsletters
  • RSS
  • Home
  • Politics
    • Economy
    • Energy & Environment
    • Gender & Sexuality
    • Health Care
    • Immigration
    • Labor
    • Science & Technology
    • World
  • Culture
    • Books
    • Film
    • Television
  • Blogs
    • Vox Pop
    • Policy Shop
  • Voices
    • Jamelle Bouie
    • E.J. Graff
    • Robert Kuttner
    • Harold Meyerson
    • Abby Rapoport
    • Robert Reich
    • Paul Waldman
    • Other Contributors ⇒
  • Magazine

Search form

RSS

Dean Baker

Dean Baker is co-director of the Center for Economic and Policy Research in Washington, D.C. He is the author of several books, including Plunder & Blunder: The Rise and Fall of the Bubble Economy, The Conservative Nanny State: How the Wealthy Use the Government to Stay Rich and Get Richer and The United States Since 1980. Read more about Dean.

Recent Articles

Energy Insurance

Dean BakerNov 09, 2001





The vast majority of scientists who study climate issues now agree that carbon emissions are a potentially disastrous problem. However, economic fears have obstructed even the mildest remedies. Particularly in the United States, voters resist taxes that would raise fuel costs, and there has been little political support for massive investment in new technologies or mass transit systems.



  • Read more about Energy Insurance
  • See the complete issue
PinItInstapaperPocketEmailPrint

Patent Medicine

Dean BakerNov 07, 2001

Absurdly high prices have put lifesaving prescription drugs out of reach for millions of Americans and for hundreds of millions of people in developing countries. In large part, patent protection is to blame. The patent system is a trade-off: Consumers pay a monopoly price on a drug for 17 years to provide incentives for firms to undertake research that yields large profits. But the patent system is not the only way to support drug research. Alternatives that have a proven track record of success already exist--specifically, research supported by foundations, universities, and the government. Shortening patent terms and putting most pharmaceutical research in the public domain would cut costs for consumers as well as for government.

  • Read more about Patent Medicine
  • See the complete issue
PinItInstapaperPocketEmailPrint

Pages

  • « first
  • ‹ previous
  • …
  • 508
  • 509
  • 510
  • 511
  • 512
  • 513
  • 514
  • 515
  • 516

© by The American Prospect

  • About Us
  • Advertise
  • Jobs/Internships
  • Masthead
  • Submissions
  • Reprints
  • Privacy Policy
  • Archive
  • Customer Service